GLUE
Monte Rosa TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
GLUE vs peer average
61/100
GLUE vs. peer average (C vs. D)
Grade spread
B 1 · C 2 · D 5 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
ALMS is the first available peer comparator.
Similar-sized clinical-stage biopharma comparator; differing programs and development risks limit direct valuation conclusions.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GLUE
Monte Rosa Therapeutics
ALMS
Alumis
Grade
C
C
Momentum
8
2
Value
41
41
Sentiment
73
79
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Grade position vs ALMS
GLUE / ALMS
Grade Position
In line
GLUE vs. peer average (C vs. D)
61/100
Momentum
8
GLUEValue
41
GLUESentiment
73
ALMSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GLUE
ALMS is the first peer returned for this comparison set.